Brief: Hutchmed (China) Says Astrazeneca Submits US NDA For Orpathys Plus Tagrisso
29/09/2026 02:50
BRIEF-Hutchmed (China) Says Astrazeneca Submits US NDA For Orpathys Plus Tagrisso Sept 29 (Reuters) - HUTCHMED (China) Ltd 0013.HK:
ASTRAZENECA SUBMITS US NDA FOR ORPATHYS PLUS TAGRISSO IN MET-DRIVEN EGFR-MUTATED LUNG CANCER
Further company coverage: 0013.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AstraZeneca
See all newsAstraZeneca says FDA approves drug for rare kidney disease in adults
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
Early US flu season, current strain may signal risk for younger people; doctors urge shots
AstraZeneca partners with Oracle for AI-driven clinical trials
Factbox: Pharma sector doubles down on AI to slash costs, timelines